SavedAdd your journal

Journals / Gülhane Tıp Dergisi / 2013 / Cilt: 55 - Sayı: 3

Impact of total core length on cancer detection rate in a 12 - core prostate biopsy scheme

12 Kadran prostat biyopsi protokolünde toplam kor uzunluğunun kanser saptanma oranına etkisi

Ufuk BERBER
Aptullah HAHOLU
Zafer KÜÇÜKODACI
İSMAİL YILMAZ
Pages
203–206
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

When a threshold of 10 cm was selected for total core length, overall cancer detection rate for < 10 cm group was 23.9% (17 / 71) and &#8805; 10 cm group was 39.5% (275 / 697).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We retrospectively investigated the core lengths of 768 patients underwent initial prostate biopsy by a lateral zone targetted 12-core protocol between 2006 and 2011, to evaluate the impact of total core length in cancer detection.
📊
Key Findings & Data:Cancer was identified in 292 (38.0%) patients.
💡
Conclusion & Impact:When a threshold of 10 cm was selected for total core length, overall cancer detection rate for < 10 cm group was 23.9% (17 / 71) and &#8805; 10 cm group was 39.5% (275 / 697).
🔬Design:Research Article
📍Scope:2006 Verileri
⚙️Variables:Domain Parameters

Abstract

We retrospectively investigated the core lengths of 768 patients underwent initial prostate biopsy by a lateral zone targetted 12-core protocol between 2006 and 2011, to evaluate the impact of total core length in cancer detection. Cancer was identified in 292 (38.0%) patients. Mean total core length for positive and negative biopsy results were 15.3 cm and 14.6 cm, respectively. Cancer detection rates in groups for total core length < 12 cm, 12 - 15 cm, and > 15 cm were 30.9% (55 / 178), 40.6% (96 / 236), and 39.8% (141 / 354) , respectively. When a threshold of 10 cm was selected for total core length, overall cancer detection rate for < 10 cm group was 23.9% (17 / 71) and &#8805; 10 cm group was 39.5% (275 / 697). Total core length has a great impact in cancer detection rate and may be used as a reliable adjunctive tool in deciding repeat biopsies for patients with negative biopsy result.

Özet

Transrektal ultrasonografi eşliğinde 12 kadran prostat biyopsi protokolünde, toplam kor uzunluğunun kanser saptanma oranına etkisini araştırmak amacı ile retrospektif olarak 2006 ve 2011 yılları arasında ilk defa prostat biyopsisi uygulanmış 768 hastada toplam kor uzunlukları ile kanser saptanma oranları incelendi. Toplam 292 (%38.0) hastada kanser saptandı. Ortalama toplam kor uzunluğu, biyopsi sonucu kanser için pozitif olan hastalarda 15,3 cm, negatif olan hastalarda ise 14,6 cm olarak bulundu. Toplam kor uzunluğuna göre biyopsiler 15 cm olarak sınıflandırıldığında kanser saptanma oranlarının sırasıyla %30.9 (55 / 178), %40.6 (96 / 236) ve %39.8 (141 / 354) olduğu saptandı. Toplam kor uzunluğu için 10 cm eşik değer olarak alındığında ise < 10 cm olan biyopsilerde kanser %23.9 (17 / 71) oranında saptanırken ≥ 10 cm biyopsi grubunda bu oran %39.5 (275 / 697) olarak bulundu. Bu sonuçlar toplam kor uzunluğunun kanser saptanma oranı üzerinde büyük bir etkisi olduğunu göstermiş ve ilk biyopsi sonucu negatif gelen hastalarda tekrar biyopsisine karar verirken kullanılabilecek objektif bir ölçüt olduğunu göstermiştir.

🔖

Cite This Article

BERBER, U., HAHOLU, A., KÜÇÜKODACI, Z., YILMAZ, İ. (2013). Impact of total core length on cancer detection rate in a 12 - core prostate biopsy scheme. Gülhane Tıp Dergisi, Cilt: 55 - Sayı: 3, 203–206. https://ajindex.com/articles/216206

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142: 71-75
  2. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: A systematic review. J Urol 2006; 175: 1605-1612
  3. Presti JC. Prostate biopsy: Current status and limitations. Rev Urol 2007; 9(3): 93-98
  4. Eskicorapci SY, Guliyev F, Akdogan B et al. Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection. J Urol 2005; 173: 1536-1540
  5. Remzi M, Fong YK, Dobrovits M, et al. The Vienna nomogram: Validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 2005; 174: 1256- 1261
  6. Loeb S, Catalona WJ. Prostate-specific antigen (PSA) should drive doing prostate biopsies. Urol Oncol 2012; 30: 1-2
  7. Naughton CK, Ornstein DK, Smith DS, Catalona WJ. Pain and morbidity of transrectal ultrasound guided prostate biopsy: A prospective randomized trial of 6 versus 12 cores. J Urol 2000; 163: 168-171
  8. Dogan HS, Aytac B, Kordan Y, Gasanov F, Yavascaoglu İ. What is the adequacy of biopsies for prostate sampling? Urol Oncol 2011; 29: 280-283
  9. Iczkowski KA, Casella G, Seppala RJ, et al. Needle core length in sextant biopsy influences prostate cancer detection rate. Urol 2002; 59: 698-703
  10. Van der Kwast TH, Lopes C, Santonja C, et al. Guidelines for processing and reporting of prostatic needle biopsies. J Clin Pathol 2003; 56: 336-340
  11. Boccon-Gibod L, Van der Kwast TH, Montironi R, Boccon-Gibod L, Bono A. Handling and pathology reporting of prostate biopsies. Eur Urol 2004; 46: 177- 181.